This looks like a darn good addition to the team. Fox.
Dimethaid announces new appointment
Monday July 25, 8:15 am ET
Company appoints Dan McKay to new position of Vice President, Intellectual Property
TORONTO, July 25 /CNW/ - Pharmaceutical developer Dimethaid Research Inc. (TSX: DMX - News) today announced that it has appointed Dan McKay to the newly created position of Vice President, Intellectual Property.
"Our restructuring efforts have been focused on returning Dimethaid to its core competency of drug development," said John London, Vice Chairman of Dimethaid. "We therefore intend to move forward on a number of initiatives to broaden and deepen our drug development pipeline, and an early priority is the creation of this new senior management role. We are delighted to welcome Dan on board and see his legal and industry experience along with a scientific background as being an ideal fit for us."
Mr. McKay has over eight years of experience in the pharmaceutical field. He joins Dimethaid from Janssen-Ortho Inc. (Johnson & Johnson) where he was responsible for intellectual property, patents, and life cycle management. Prior to his tenure at J&J, Mr. McKay honed his pharmaceutical and intellectual property experience with Toronto-based law firms Bereskin & Parr and Gowling, Lafleur & Henderson.
Along with his expertise in intellectual property, Mr. McKay has considerable experience in a number of other key areas including drug delivery, pricing, business development and federal affairs. As a member of the intellectual property committee at Rx&D, Mr. McKay has been a strong advocate before industry and government for amending the patent regulations to recognize novel dosage forms.
Mr. McKay holds a BSc in molecular biology from McGill University and is a graduate of Osgoode Hall Law School.
About Dimethaid |
